KR102134305B1 - 혈액응고반응의 평가방법 - Google Patents

혈액응고반응의 평가방법 Download PDF

Info

Publication number
KR102134305B1
KR102134305B1 KR1020157010558A KR20157010558A KR102134305B1 KR 102134305 B1 KR102134305 B1 KR 102134305B1 KR 1020157010558 A KR1020157010558 A KR 1020157010558A KR 20157010558 A KR20157010558 A KR 20157010558A KR 102134305 B1 KR102134305 B1 KR 102134305B1
Authority
KR
South Korea
Prior art keywords
coagulation
coagulation factor
activity
blood
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157010558A
Other languages
English (en)
Korean (ko)
Other versions
KR20150068406A (ko
Inventor
테츠히로 소에다
다케히사 기타자와
미도리 시마
Original Assignee
추가이 세이야쿠 가부시키가이샤
고리츠다이가쿠호징 나라켕리츠 이카다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤, 고리츠다이가쿠호징 나라켕리츠 이카다이가쿠 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20150068406A publication Critical patent/KR20150068406A/ko
Application granted granted Critical
Publication of KR102134305B1 publication Critical patent/KR102134305B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6443—Coagulation factor XIa (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157010558A 2012-09-28 2013-09-26 혈액응고반응의 평가방법 Active KR102134305B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012217925 2012-09-28
JPJP-P-2012-217925 2012-09-28
PCT/JP2013/075978 WO2014050926A1 (ja) 2012-09-28 2013-09-26 血液凝固反応の評価方法

Publications (2)

Publication Number Publication Date
KR20150068406A KR20150068406A (ko) 2015-06-19
KR102134305B1 true KR102134305B1 (ko) 2020-07-15

Family

ID=50388321

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157010558A Active KR102134305B1 (ko) 2012-09-28 2013-09-26 혈액응고반응의 평가방법

Country Status (13)

Country Link
US (1) US11078518B2 (https=)
EP (1) EP2902787B1 (https=)
JP (1) JP6284481B2 (https=)
KR (1) KR102134305B1 (https=)
CN (1) CN104937423B (https=)
BR (1) BR112015006634B1 (https=)
CA (1) CA2886326C (https=)
ES (1) ES2668455T3 (https=)
MX (1) MX358997B (https=)
PL (1) PL2902787T3 (https=)
RU (1) RU2683933C2 (https=)
TW (1) TWI609083B (https=)
WO (1) WO2014050926A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
CN107533071A (zh) 2015-04-24 2018-01-02 公立大学法人奈良县立医科大学 血液受试体的凝固能力的评价方法、以及用于在该方法中使用的试剂、试剂盒及装置
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
JP7101351B2 (ja) * 2016-04-28 2022-07-15 シスメックス株式会社 血液検体の分析方法、血液検体分析用試薬及び試薬キット、並びに血液検体分析装置
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
RU2699798C1 (ru) * 2019-05-22 2019-09-11 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России) Способ выявления дефицитов факторов свертывания крови методом тромбоэластометрии
JP6883899B1 (ja) * 2020-12-07 2021-06-09 株式会社血栓トランスレーショナルリサーチラボ 血液凝固検査試薬、および血液凝固検査方法
US12588235B2 (en) 2022-01-27 2026-03-24 Vanguard International Semiconductor Corporation Semiconductor structure and manufacturing method of the same
WO2024143525A1 (ja) 2022-12-28 2024-07-04 積水メディカル株式会社 血液検体の血液凝固能の分析方法
WO2024143524A1 (ja) 2022-12-28 2024-07-04 積水メディカル株式会社 血液検体の血液凝固能の分析方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2746386B2 (ja) 1988-09-07 1998-05-06 清水製薬株式会社 全血を用いた血液凝固能検査法
US20070041978A1 (en) * 2003-10-10 2007-02-22 Kunihiro Hattori Bispecific antibody substituting for functional proteins
JP2007504812A (ja) * 2003-09-12 2007-03-08 バクスター・インターナショナル・インコーポレイテッド 第ＶＩＩＩａ因子様活性を示す第ＩＸａ因子特異抗体
JP2012082201A (ja) 2005-04-08 2012-04-26 Chugai Pharmaceut Co Ltd 血液凝固第ｖｉｉｉ因子の機能代替抗体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK162233C (da) * 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0638127T3 (da) * 1992-04-27 2000-12-18 Avocet Medical Inc Testartikel og fremgangsmåde til at udføre blodkoagulationsanalyser
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AT405692B (de) * 1997-03-27 1999-10-25 Immuno Ag Reagens zur bestimmung der aptt
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
DE102005008066A1 (de) * 2005-02-22 2006-08-24 Haemosys Gmbh Verfahren zur Bestimmung der Gesamtgerinnungsaktivität einer Blut- oder Plasmaprobe
CN101415445A (zh) * 2006-03-31 2009-04-22 巴克斯特国际公司 聚乙二醇化的因子ⅷ
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US20140296146A1 (en) 2011-08-23 2014-10-02 Synapse B.V. Thermostable Inhibitors of Activation of the Blood Clotting System Through Contact with Foreign Surfaces

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2746386B2 (ja) 1988-09-07 1998-05-06 清水製薬株式会社 全血を用いた血液凝固能検査法
JP2007504812A (ja) * 2003-09-12 2007-03-08 バクスター・インターナショナル・インコーポレイテッド 第ＶＩＩＩａ因子様活性を示す第ＩＸａ因子特異抗体
US20070041978A1 (en) * 2003-10-10 2007-02-22 Kunihiro Hattori Bispecific antibody substituting for functional proteins
JP2012082201A (ja) 2005-04-08 2012-04-26 Chugai Pharmaceut Co Ltd 血液凝固第ｖｉｉｉ因子の機能代替抗体

Also Published As

Publication number Publication date
CA2886326C (en) 2021-11-02
TWI609083B (zh) 2017-12-21
BR112015006634B1 (pt) 2022-06-14
EP2902787B1 (en) 2018-03-28
US11078518B2 (en) 2021-08-03
PL2902787T3 (pl) 2018-08-31
HK1212443A1 (en) 2016-06-10
CA2886326A1 (en) 2014-04-03
CN104937423A (zh) 2015-09-23
MX2015003740A (es) 2015-09-23
WO2014050926A1 (ja) 2014-04-03
MX358997B (es) 2018-09-12
BR112015006634A2 (https=) 2017-09-05
RU2683933C2 (ru) 2019-04-03
CN104937423B (zh) 2017-05-24
KR20150068406A (ko) 2015-06-19
TW201418470A (zh) 2014-05-16
EP2902787A4 (en) 2016-03-23
EP2902787A1 (en) 2015-08-05
US20150240287A1 (en) 2015-08-27
JPWO2014050926A1 (ja) 2016-08-22
JP6284481B2 (ja) 2018-02-28
ES2668455T3 (es) 2018-05-18
RU2015115277A (ru) 2016-11-20

Similar Documents

Publication Publication Date Title
KR102134305B1 (ko) 혈액응고반응의 평가방법
US12600798B2 (en) Medicinal composition usable for preventing and/or treating blood coagulation factor IX abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor VIII
KR102057767B1 (ko) 응고 인자 및 다중특이적 항체의 조합 요법
DK2373691T3 (en) ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE
RU2739946C2 (ru) Антитела к фактору xi и способы их применения
ES2542330T3 (es) Polipéptidos terapéuticos, homólogos de los mismos, fragmentos de los mismos y su uso en modular la agregación mediada por plaquetas
WO2011022335A1 (en) Methods of using cd44 fusion proteins to treat cancer
CN115884986A (zh) 抗蛋白s单域抗体和包含其的多肽
HK1212443B (en) Method for evaluating blood coagulation reaction
JP2012529445A (ja) 線溶亢進を伴う凝固障害の処置
HK40010041A (en) Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
La Manna et al. Triple-negative breast cancer: new potential therapeutics derived from SOCS3 protein
US20150005238A1 (en) Treatment of coagulopathy with hyperfibrinolysis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150423

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180703

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190719

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200526

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200709

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200709

End annual number: 3

Start annual number: 1

PG1601 Publication of registration